Among them, immune checkpoint blockade using antibodies to block immune checkpoint pathways, such as the programmed cell death protein 1 pathway (PD-1/PD-L1), has been demonstrated to be an effective strategy in treating different types of cancers in the clinic (27). The gene discussed is CD274; the disease is cancer.